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Autoantibodies make a U-turn: the toll hypothesis for 
autoantibody speciﬁcity
 
David A. Martin and Keith B. Elkon
 
Like the immune response itself, our efforts to understand the “rules” for self–
nonself discrimination are constantly evolving. The discovery of pattern 
recognition receptors—the Toll-like receptor (TLR) family in particular—shifted 
the emphasis of self–nonself recognition from lymphocytes functioning in the 
adaptive immune system to antigen-presenting cells (APCs) functioning in the 
innate immune system. Two new articles, one in a recent issue (1) and one in 
this issue (see Vollmer et al. [2] on p. 1575), demonstrate that antigen–
antibody complexes containing RNAs activate B lymphocytes and dendritic 
cells (DCs) through interaction with TLR7 and/or TLR8. From these and other 
papers, one begins to see how specific types of autoantigens—by virtue of their 
capacity to act as TLR ligands—favor autoantibody production. This is known 
as the Toll hypothesis.
 
Recent discoveries set the stage for
the experiments described by Lau et al.
(1) and Vollmer et al. (2). A major ob-
servation was that mammalian DNA
(likely in the form of chromatin) acti-
vated B cells or DCs when endocytosed
through the B cell receptor (BCR) or
Fc
 
 
 
R, respectively (3, 4). This debunked
the concept that TLRs dependably dis-
tinguish self from foreign and thus alert
the host to “danger.” In addition to
mammalian DNA, certain single stranded
viral RNAs and mammalian RNAs, es-
pecially those rich in uridine (U) or
uridine and guanine (UG), were found
to be biological agonists for TLR7/8
(5, 6), which are expressed in human B
cells (TLR7), plasmacytoid DCs (TLR7),
and myeloid DCs (TLR7/8) (7). Finally,
Ronnblom and colleagues (8) made the
observation that serum from patients
with lupus stimulated type I interferon
(IFN) production when incubated with
apoptotic cells, and that this response
was attenuated by RNase.
The article by Lau et al. (1) extends
the “two receptor paradigm” previously
described for endogenous DNA–Ig im-
mune complexes to complexes con-
taining endogenous RNA. The authors
observed that IFN-primed B cells ob-
tained from mice transgenic for rheuma-
toid factor proliferated after exposure to
Sm–ribonucleoprotein (RNP) immune
complexes. This activity was both RNase
sensitive and TLR7 dependent. Further-
more, they observed that autoantibody
production was significantly ameliorated
in the absence of the TLR adaptor pro-
tein MyD88 in lupus-prone mice.
Vollmer et al. (2) also demonstrated
the ability of mammalian RNP particles
to stimulate innate responses. Using a
series of synthetic oligoribonucleotides,
they showed that highly conserved
U-rich RNAs activated plasmacytoid
DCs via TLR7 and monocytes and my-
eloid DCs via TLR8. Vollmer et al. also
showed that sera from lupus patients
with anti-RNP antibodies stimulated
IFN production from PBMCs or plas-
macytoid DCs via CD32 (Fc
 
 
 
RIII).
Here, we discuss autoantibody for-
mation in systemic lupus erythematosus
(SLE), where the Toll hypothesis is
particularly appealing. SLE is an auto-
immune disease characterized in part by
the presence of serum autoantibodies that
recognize nucleoprotein antigens, such as
Sm and RNP. These endogenous core
proteins are tightly bound to U-rich
small nucleotide (sn)RNAs (including
U1, 2, 4, 5, and 6). The fact that these
snRNAs are U rich makes them appro-
priate targets to test for immune stimu-
lation through TLR7/8. Although the
studies by Lau et al. and Vollmer et al.
come to similar conclusions with regard
to self RNA-induced immune activa-
tion, they raise questions that are central
to our understanding of autoantibody
generation and autoimmunity in general.
Some of these questions are discussed
below.
 
Do RNPs both initiate and perpetuate 
autoimmunity?
 
Perhaps the most fundamental question
to arise from these and other studies is
whether TLR activation is critical for
both the initiation and perpetuation of
autoantibody production. Mammalian
DNA or RNA must enter discrete en-
docytic compartments within the cell
in order to interact with intracellular
TLRs (such as TLR3, 7, 8, and 9). The
only way that this has been achieved
experimentally without the use of
transfection is through engagement of
IgG–nucleoprotein complexes with the
antigen receptor on B cells or Fc
 
 
 
 re-
ceptors on DCs (8). Furthermore, the
most robust responses were observed
when the target cells were first “primed”
by exposure to IFN-
 
 
 
 or CD40 ligand
(CD40L) (1, 2), a phenomenon ex-
plained in part by the IFN-
 
 
 
– or
CD40L-induced up-regulation of TLR7.
From these in vitro studies, one can infer
that during immune activation and after
the production of antinucleoprotein
autoantibodies—in other words, when
tolerance has already been broken—the
pathways described in these articles are
likely to perpetuate immune activation
and autoimmunity in vivo.
Could the same pathways be invoked
in the initiation of autoimmunity?
Viglianti et al. (9) showed that chroma-
tin ingestion can occur through direct
binding of chromatin to the BCR on B
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cells derived from transgenic mice ex-
pressing a DNA-specific BCR, and that
this chromatin ingestion triggers B cell
proliferation. If B cell proliferation
equates with maturation and autoanti-
body production (as yet unproven as-
sumptions, as discussed below), then
the uptake of nucleoproteins directly
through the BCR may initiate autoan-
tibody production. However, as low-
affinity antibodies specific for self-
DNA or RNA are thought to be abun-
dant in the peripheral circulation (10),
the avidity of interaction between the
BCR and nucleoprotein, as well as the
downstream signaling responses trig-
gered by this interaction, and/or other
environmental influences may be criti-
cal in determining whether pathogenic
autoantibodies are produced. Perhaps
exposure to IFN-
 
 
 
 or other inflamma-
tory cytokines, produced in response to
inflammatory proteins released by dy-
ing cells (11), are necessary coconspira-
tors that are required to prime the
immune system toward exaggerated
responses. It is also possible that this
process is sustained by defective clear-
ance of apoptotic cells (12) (Fig. 1 A). In
addition, failure to establish self-toler-
ance during early B cell development
allows the escape of autoreactive B cells,
as recently shown in a small number of
untreated SLE patients (13). If these B
cells have sufficient avidity for self-
nucleoproteins with repetitive epitopes
that cross-link the BCR, the cells could
become activated, endocytose the nu-
cleoprotein, and be stimulated through
their TLRs (Fig. 1 B and Fig. 2).
 
Does TLR binding by nucleoproteins 
explain autoantibody specificity?
 
Throughout the decades after the dis-
covery of autoantibodies in patients
with lupus and related diseases, interest
in these antibodies has waxed and
waned. Although often dismissed as
epiphenomena, the remarkable disease
specificity of these autoantibodies, as
well as the association between certain
autoantibodies and disease manifesta-
tions (10), suggest that an understanding
of how these antibodies are generated
might provide insight into the mecha-
nisms of disease. As autoantibodies in
SLE patients recognize components of
chromatin (such as dsDNA, histones,
and nucleosomes) and U-rich ribonu-
cleoproteins (such as RNP and Sm)—
all particles that are now known to acti-
vate TLRs (10)—it can be proposed
that selection of these particles for im-
mune attack is based on their intrin-
sic ability to activate the TLRs—the
Toll hypothesis. This hypothesis would
explain why most autoantigens in
SLE and related diseases are nucle-
oproteins—the nucleic acid component
could serve as the adjuvant that stimu-
lates cytokine production and the up-
regulation of costimulatory molecules,
thus facilitating the presentation of the
associated peptides to T cells (Fig. 2).
Sm/RNP is a particularly appropri-
ate model antigen, as the highly con-
served domains of Sm that make up the
hexameric or heptameric rings of the
protein (Fig. 2) bind to the oligo-U
consensus sequence RAU5GR (where
R is any purine) on U snRNAs (for re-
view see reference 14). If the Toll
hypothesis is correct, other common
RNP antigens that are targeted in SLE,
such as Ro (SSA) and La (SSB), should
also be TLR agonists. Vollmer et al.
(2) report that two small Ro RNAs
areTLR7/8 agonists. But what about
La? La associates with the 3
 
 
 
 termini of
a variety of newly synthesized small
RNAs (including the RNA polymerase
III transcripts, Ro Y RNAs, U6, pre-
tRNAs, pre-5S, and 7SL RNA, as well
as small viral RNAs) and, at least in
yeast, with polymerase II transcripts
(15). A unifying explanation for the
binding of RNPs to these nascent tran-
scripts is recognition of a short 3
 
 
 
 oligo
U tract, UUU-OH.
It remains to be experimentally
tested whether Ro, La, and other ribo-
Figure 1. Possible mechanisms by which nucleoprotein antigens initiate autoantibody 
production. (A) A virus infection is sensed by TLRs in plasmacytoid dendritic cells (pDCs) resulting in 
the production of large concentrations of type I interferon (IFN- / ). IFNs prime the adaptive immune 
system to respond to other signals that may include nucleoprotein antigens released from dead and 
dying cells. Virus persistence and/or defective clearance of apoptotic cells might drive chronic, self-
perpetuating autoimmunity through uptake of nucleoprotein antigen–antibody complexes (Fig. 2). 
(B) Defective B cell tolerance leads to capture of nucleoprotein antigens by autoreactive B cells, 
thereby triggering B cell activation, TLR stimulation, and antigen presentation to T cells. Apoptotic 
cells are abundant in germinal centers, and nucleoprotein antigens may be released at other sites due 
to abnormal cell death or defective cell clearance.
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nucleoprotein antigens that are targeted
in SLE are preferential activators of
TLR7/8. But the large number of pos-
sible U-rich regions in RNAs of the
snRNP family (which includes at least
12 members), of small nucleolar RNAs
(which number in the hundreds), and
of mRNAs that contain 3
 
 
 
 U-rich re-
gions, suggest that the property of be-
ing U, UG, or G rich is itself unlikely
to be a sufficient explanation for au-
toantibody selection through TLR ac-
tivation. Could there be stimulatory se-
quences within these RNAs similar to
those described for DNA and, more
recently, for small interfering RNAs
(16)? Could one or more of the more
than 100 known biochemical modifi-
cations of RNA, such as methylation
or pseudouridylation, explain differ-
ences in activation potential? Recently,
it was shown that several of the modifi-
cations that occur primarily in mam-
malian, but not in bacterial, RNAs
protected transfected cells from intra-
cellular TLR stimulation (17). This sit-
uation is analogous to the protective
methylation of DNA in mammalian
cells. Finally, the high abundance of
U1 RNA (10
 
6
 
 copies per nucleus) and
the tight binding between the nucleic
acid and the core proteins may confer a
relative insensitivity to nucleases and
the persistence of the particles both
outside and inside the cell.
If immunostimulatory DNA and
RNA sequences or structures help to
account for autoantibody specificity in
SLE, and very likely in Sjogren’s syn-
drome (18), a prediction is that the
dominant nucleoprotein autoantigens
in other systemic diseases, such as sys-
temic sclerosis and polymyositis, will
also stimulate TLRs.
 
Innate immunity to self-nucleoproteins
 
If self–nucleic acids are capable of acti-
vating TLRs, how does the immune
system avoid autoimmune activation of
the sort described by Lau et al. (1) and
Vollmer et al. (2)? The answer likely
lies in the intracellular and intraendoso-
mal location of TLR3, 7, 8, and 9, and
the presence of highly abundant extra-
and intracellular nucleases. Serum con-
tains high levels of DNase and RNase
activity, which presumably help dis-
solve nucleic acids that leak out of dead
and dying cells, particularly at sites of
inflammation. A plethora of nucleases
also exist within the cell—some that as-
sist in the processing of nucleic acid in-
termediates and others that appear to
degrade foreign or ectopic nucleic ac-
ids. Type II DNases function optimally
in an acidic environment (such as in en-
dosomes/lysosomes), the DNase1-like
(L) family have been variously proposed
to act in the nucleus, cytosol, and extra-
cellular space, and several other DNases
(such as caspase-activated DNase and
endonuclease G) are required for cell-
autonomous DNA degradation (19–
21). The inability to degrade DNA in
DNase II
 
 
 
/
 
 
 
 mice results in high levels
of IFN-
 
 
 
 production, although inter-
estingly the inefficient removal of en-
gulfed endogenous DNA stimulates
innate immunity through a TLR9-
independent pathway (22).
Extracellular or secretory RNases
of the RNase A superfamily have a
wide range of activities as demonstrated
by differential catalytic activities on
substrates such as single or double
stranded RNA and poly-C or poly-U
(for review see reference 23). Intracel-
lular RNases are extremely diverse and
comprise not only proteins but also
catalytic RNAs. SmRNP itself, as part
of the spliceosome, excises intronic
RNA from pre-mRNA by transesteri-
fication reactions. Many RNases func-
tion in processing events at the 5
 
 
 
 or 3
 
 
 
region of the RNA, whereas others
are  selectively catalytic for RNA/
DNA hybrids (such as the RNase H
family) or double stranded RNA (such
as the RNase III superfamily), which
include the recently recognized Dicer—
the enzyme required for the genera-
tion of small interfering RNAs. Two
enzymes, RNase L and ISG20, help to
Figure 2. Possible mechanisms by which engagement of the U1 snRNP antigen activates 
APCs. (1) The U1 snRNP binds to the BCR on a B cell or Fc R on a DC. (2) Cross-linking of the receptor 
results in an activation signal. (3) The receptor is endocytosed, and the endosome matures into a late 
endosome/lysosome containing TLR7 and 8. (4) The U-rich RNA, initially protected by the SmRNP proteins 
and/or the antibody, now engages the TLR triggering activation of IRF and NF- B signal transduction 
pathways. (5) The protein component dissociates and is degraded by lysosomal enzymes with mem-
brane fusion to vesicles containing MHC class II. (6) Activated transcription factors induce expression 
of proinflammatory cytokines such as type I IFNs, IL-12, IL-6, and TNF which (7) up-regulate MHC 
class II and costimulatory molecule expression. Cell activation may also lead to cell proliferation.
 
20052228  Page 1467  Wednesday, November 23, 2005  3:32 PM 
DO TLR
 
S
 
 EXPLAIN AUTOANTIBODY SPECIFICITY? | D.A. Martin and K.B. Elkon
 
1468
 
degrade viral RNAs and are of particu-
lar interest, as they are induced by type
I IFNs.
As mentioned previously, U-rich
RNAs in SmRNP may be relatively
resistant to nuclease attack. Endoso-
mal location cannot be the only ex-
planation for this resistance, as sn-
RNPs are assembled in the cytoplasm
before their reimport into the nucleus.
Whether  resistance is conferred by
high-affinity binding of RNAs to pro-
teins or by specific patterns of protein
shielding, nucleoprotein stability may
be an important requirement for TLR
stimulation.
 
Are TLRs the B all and end all?
 
Two important consequences of
TLR7/8 activation were demonstrated
in these new studies. Lau et al. (1) re-
ported that immune complexes contain-
ing RNA stimulated B cell proliferation,
but they did not show that stimulation
led to B cell maturation and autoanti-
body production. Although lymphocyte
proliferation is often followed by matu-
ration, this is not always the case. For
example, CD8
 
 
 
 T cell proliferation in
response to self-antigen is followed by
death—one mechanism of peripheral
tolerance (24). Studies on the fate of B
cells activated by nucleoprotein com-
plexes are eagerly awaited.
In the study by Vollmer et al. (2),
the major consequence of TLR7/8 ac-
tivation by U-rich RNAs was the pro-
duction of IFN-
 
 
 
, a cytokine long
known to be elevated in patients with
SLE. Although the low IFN response
in TLR7
 
 
 
/
 
 
 
 mice suggests a dominant
role for this receptor in response to U1
RNA, it is relevant to note that both
viral and mammalian nucleic acids may
stimulate IFNs through TLR-indepen-
dent routes, as recently shown (25–27).
Of particular interest, RNA helicases
containing caspase-recruiting domains
(CARDs), such as RIG-1 and Mda5,
stimulate IFN production in response
to intracellular, double stranded viral
RNA in a TLR-independent manner
(28, 29). It is thus likely that additional
nucleic acids sensors and pathways will
be discovered.
 
Clinical implications
 
Regardless of whether TLR engage-
ment is required for the initiation and/
or progression of autoantibody produc-
tion, modulation of certain TLR path-
ways impacts autoantibody production,
at least in murine models of SLE. Al-
though studies performed to date have
used mice with a mixed genetic back-
ground, they have consistently shown
that both MyD88 and TLR9 deficien-
cies reduced the level of serum autoan-
tibodies (1, 30), suggesting that these
pathways are required for high titer
autoantibody production. TLR3 defi-
ciency, in contrast, had no effect. Al-
though TLR9 deficiency reduced some
anti-DNA antibodies, it did not protect
mice from glomerulonephritis (30).
This could occur either because the
lack of TLR9 altered the isotypes or af-
finity of the anti-DNA antibodies (not
tested in this study), or because nephri-
tis was caused by a different subset of
autoantibodies. Since oligonucleotide-
based inhibitors of both TLR9 and 7
have been developed (31), their thera-
peutic application for treatment of SLE
is an exciting prospect (32).
 
Concluding remarks
 
There is currently no unifying hypoth-
esis to explain autoantigen selection in
systemic autoimmune disorders. Here,
we propose that a necessary property
for the selection of nucleoprotein au-
toantigens is their ability to activate in-
tracellular TLRs. According to the Toll
hypothesis, the nucleic acid component
of RNPs serves as an adjuvant, and the
protein component is processed by the
activated APC and presented to T cells
(Fig. 2). However, this is not a suffi-
cient explanation for autoimmunity.
Other critical abnormalities that sensi-
tize immune cells and provide a con-
stant source of antigen, or that facilitate
uptake of nucleoproteins (Fig. 1), must
act as predisposing factors. Neverthe-
less, at least part of the answer to the
50-yr-old puzzle of autoantibody spec-
ificity now seems to be solved.
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